Buy Pegadria 20 Pegylated Liposomal Doxorubicin Hydrochloride

Pegadria 20 contains pegylated liposomal doxorubicin hydrochloride, a chemotherapy medication used for cancer treatment. This 2mg/ml*10ml vial formulation is designed for intravenous administration. It is prescribed under medical supervision for specific oncology indications.

Strength

2mg/ml*10ml

Manufacturer / TM Owner

Intas Pharmaceuticals Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Pegadria 20 is used to treat certain types of cancer, including metastatic breast cancer and ovarian cancer. It may also be prescribed for other cancers as determined by a healthcare provider. This medication works by slowing or stopping cancer cell growth. Patients often ask, 'what is Pegadria 20 used for' when discussing treatment options with their doctor.

Side Effects

Pegadria 20 may cause side effects such as nausea, fatigue, or hair loss. Some patients experience changes in skin or nail color. These effects vary by individual and are typically monitored during treatment. Regular check-ups help assess how the body responds to the medication.

Precautions & Warnings

Pegadria 20 should be handled with care, as it may cause harm if it comes into contact with skin or mucous membranes. Patients should inform their healthcare provider about all medications and health conditions before starting treatment. Pregnant or breastfeeding individuals should discuss risks with their doctor.

Avoid Interactions

Pegadria 20 may interact with other medications, including certain chemotherapy drugs or CYP450 inhibitors. Patients should avoid alcohol and herbal supplements unless approved by a doctor. Vaccinations may need adjustment during treatment. Always disclose all current medications to your healthcare provider.

References

Frequently Asked Questions

Pegadria 20 is used to treat certain cancers, including metastatic breast cancer and ovarian cancer, as prescribed by a healthcare provider.

Pegadria 20 is given as an intravenous infusion under medical supervision. The exact dosage and schedule depend on the patient's condition.

Common side effects may include nausea, fatigue, hair loss, and changes in skin or nail color. These should be reported to a healthcare provider.

Pegadria 20 may harm an unborn baby. Patients should discuss risks and alternatives with their doctor if pregnant or planning pregnancy.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.